The Committee’s recommendations are submitted to the director of the CDC and become official CDC policy once approved. These recommendations are then published in the CDC’s Morbidity and Mortality Weekly Report.
At its most recent meeting, held from June 26, 2024 to June 28, 2024, the ACIP reviewed data on disease burden, vaccination effectiveness, and safety, among other issues. The ACIP panel of experts voted on vaccination recommendations for the upcoming respiratory virus season and recommendations for vaccinations to protect against some bacterial diseases.
The ACIP recently approved the following recommendations by majority vote, and they were also approved by the CDC director:
Respiratory Syncytial Virus (RSV) Vaccines–Adults
• ACIP recommends that adults aged 75 years and older receive a single dose of the RSV vaccine.
• ACIP recommends adults aged 60 to 74 years and older who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.
(NOTE: RSV vaccination is recommended as a single lifetime dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose. These recommendations supplant the current recommendation that adults aged 60 years and older may receive RSV vaccination using shared clinical decision-making. Adults aged 60 to 74 years who are NOT at increased risk of severe RSV disease are NOT recommended to receive RSV vaccination. The CDC will publish clinical considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.)
DTaP-IPV-Hib-HepB Vaccine
• ACIP recommends that DTaP-IPV-Hib-HepB should be included with PRP-OMP in the preferential recommendation for American Indian and Alaska Native infants based on the Haemophilus influenzae type b (Hib) component.
COVID-19 Vaccines
• ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by the FDA in persons aged ≥6 months.
• The updated 2024-2025 COVID-19 vaccine is expected to be available in fall 2024 with the goal of providing the best protection against currently circulating strains.
Influenza Vaccines
• ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications.
• ACIP recommends high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IIV3s or RIV3.
• The updated 2024-2025 flu vaccines will all be trivalent and protect against H1N1, H3N2, and a B/Victoria lineage virus.
Pneumococcal Vaccines
• ACIP recommends PCV21 as an option for adults aged ≥19 years who currently have a recommendation to receive a dose of PCV.
Meningococcal Vaccines
• ACIP is revisiting the adolescent meningococcal vaccine schedule to optimize protection for the higher risk ages, considering the recent epidemiology, the duration of vaccine-induced protection, and the availability of a new pentavalent (ABCWY) vaccine. This discussion will continue at the October 2024 ACIP meeting.
The current ACIP recommendations can be found on the CDC website:
http:\\www.cdc.gov/vaccines/acip/recommendations.html or
http:\\www.cdc.gov/media/releases/2024/s-0627-immunization-practices-meeting.html
The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.
